MedTrace Logo

A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo

NCT07712523 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-07-17

No results posted yet for this study

Summary

To evaluate the efficacy of QY201 Tablets in adult subjects with non-segmental vitiligo, and to provide evidence for dose selection in the confirmatory Phase III clinical trial.

Conditions

  • Adult Subjects With Non-Segmental Vitiligo

Interventions

DRUG

QY201 Tablets(5mg）

One tablet twice daily for 168 consecutive days

DRUG

QY201 Tablets（10mg）

One tablet twice daily for 168 consecutive days

DRUG

QY201 Tablets（20mg）

One tablet twice daily for 168 consecutive days

DRUG

QY201 Placebo Tablets

One tablet twice daily for 168 consecutive days

Sponsors & Collaborators

  • E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-05
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07712523 on ClinicalTrials.gov